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Bridging the Gaps between Fundamental, Preclinical and 
Clinical Research: Report from a Global HIV Vaccine 
Enterprise Working Group
Lawrence Corey , Brigitte Autran  & Louis Picker on behalf of a Working Group convened by the Global HIV 
Vaccine Enterprise
A. IntroductIon
The Global HIV Vaccine Enterprise (the Enterprise) convened a two-day 
workshop on 17-18 September 2009, at the Enterprise offices in New 
York; to discuss approaches to bridging the gaps between fundamental, 
preclinical and clinical HIV vaccine research. The topic of this Working 
Group originated from discussions of the Enterprise Science Committee, 
which proposed that more effective collaboration between these three 
areas of HIV vaccine research is needed in order to accelerate the pace 
of scientific progress in the field. Because the meeting took place before 
the release of the RV144 trial results held in Thailand1, the conclusions 
reached during the meeting were further discussed during consultations 
at scientific conferences and at a joint meeting of the Science Committee 
and Chairs of all five Working Groups. Thus, this Report reflects both 
the original discussions of the Working Group and subsequent discus-
sions that took place after the release of the RV144 trial results. Members 
of the Working Group have reviewed this Report.
During the meeting, Working Group members emphasized the unique 
role of efficacy trials in testing the ability of different vaccine concepts to 
induce protective immune responses in humans. The results of the four 
HIV vaccine efficacy trials that have been conducted to date were not 
generally anticipated and have deeply influenced directions of research. 
Failure of the VaxGen candidate to induce immunological protection2 
accelerated the shift in the field toward cell-based vaccines; the early 
termination of the Step trial3 was viewed by many as the failure of a cell-
based vaccine strategy; while the results of the RV144 trial1 have now 
brought new attention to the possible role of innate immune responses 
and non-neutralizing antibody functions as keys to achieving protection 
and the importance of CD4+ T cell responses after vaccination. These 
shifts in the conceptual framework on how to best design an effective 
HIV vaccine reflect both the current very limited understanding of the 
pathways to immunological protection4, and the view that the main pur-
pose of efficacy trials is to advance a vaccine product toward licensure. 
However, the most significant contribution of these trials has been to 
deepen our scientific understanding of vaccine-induced responses and 
their effects on HIV. For example, even though the Step vaccine showed 
no efficacy, post-hoc analyses from this trial have provided evidence of 
sieve effects on viral diversity in breakthrough infections3,5, the narrow 
breadth of elicited T-cell responses6, and the possible role of preexist-
ing vector immunity in increasing susceptibility to HIV3. At the same 
time, advances in laboratory and computational tools are providing 
new opportunities for rigorous scientific investigation in humans. It 
is imperative to recognize that the next efficacy trial(s) may not lead to 
a licensable product; as such, we have to do a better job of integrating 
scientific inquiry into trial protocols from the beginning to maximize 
learning opportunities. Importantly, while this conclusion was reached 
before the Thai trial results were known, subsequent discussions have 
reinforced this view and underpinned the call for scientifically-rich 
clinical trials. The efficacy results of the RV144 prime-boost strategy, 
albeit modest, have provided new impetus to search for correlates of pro-
tection. At the same time, recent advances in fundamental biomedical 
research and HIV biology have increased the likelihood that this search 
for correlates will be successful. However, to take full advantage of these 
advances, the field needs to explore ways to bridge the gap between 
clinical and basic research.
The Working Group also discussed the very important role that non-
human primate (NHP) studies play in HIV vaccine research. It was 
agreed that the ability of currently used animal models to predict the 
outcome of vaccination in humans is uncertain, and therefore, that dem-
onstration of immunogenicity and/or efficacy by a vaccine candidate in 
NHPs, while desirable, is not absolutely necessary for advancement of 
the candidate to clinical trials. Instead, the focus of NHP research should 
be on those fundamental questions of viral-host interactions that cannot 
be easily addressed in humans. Two areas of particular importance were 
identified: first, a focus on dissecting the immunologic mechanisms 
responsible for protection against virus challenge; and second, under-
standing early immunological events, especially at mucosal surfaces, 
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careful examination of immunogenic and protective properties of vac-
cine regimens. Exploring novel clinical trial and statistical methods to 
support the design, ethical review, and conduct of discovery-oriented 
efficacy trials is a scientific imperative.
Scientifically-enriched clinical trials require a comprehensive inves-
tigation of immunogenic properties of vaccines, which can only be 
achieved by cutting-edge assays and by extensive and sophisticated sam-
pling. The Working Group identified two approaches to addressing this 
need. First, new and better technologies have to be developed that can 
be used in the large-scale, often low-resources settings of HIV vaccine 
efficacy trials. Such areas as mucosal immunity and innate responses are 
particularly challenging (for example, many of the innate responses are 
lost during the freeze-thaw of cells). Second, the carrying out of assays 
in the host countries where trials are conducted would greatly accelerate 
and facilitate the clinical trial process.
Priority 2: optimize the use of nHPs through improved 
relevance to humans and closer integration of preclinical and 
clinical research
In addition to the need for closer connections between basic and clini-
cal scientists, communications between clinical scientists and scientists 
studying NHP models of HIV infection need to be strengthened. The 
full value of the NHP models will only be realized if findings from the 
model are efficiently translated into human trials. Collaborations need to 
focus on using NHP models to test vaccine concepts, prioritize vaccine 
strategies (although not serve as a gatekeeper for human experiments), 
and inform hypothesis-driven clinical trials.
recommendations
There is a wealth of clinically-relevant information that can be obtained 
from NHP models of HIV/AIDS, but probably the most important is 
the understanding of interactions between the virus and the host during 
the very early events (within the first 96 hours) after infection, those 
interactions governing the initial “take” of the infection and early ampli-
fication leading to systemic spread. Such events are currently very dif-
ficult, if not impossible, to study in humans, but can be pursued in the 
NHP model. Specifically, NHP research may help uncover viral vulner-
abilities to diverse immune effector mechanisms and define vaccina-
tion approaches necessary for specifically eliciting and maintaining such 
effective immune responses.
It is now generally accepted that the NHP models have not been fully 
developed or their potential fully realized in HIV vaccine research. 
One issue is the plethora of models used in different laboratories, with 
relatively limited understanding of how these models relate to each 
other and, more importantly, the extent to which each one relates to 
human HIV infection. In addition, the small sample sizes used in most 
NHP experiments make definitive conclusions and comparisons dif-
ficult. Thus, the NHP field needs to create appropriate incentives and 
occurring at the earliest times after vaccination or infection. Answers to 
key questions in these areas are critical to understand how vaccines may 
elicit protection against HIV and to stimulate generation and testing of 
new hypotheses and vaccine concepts. It was recognized that this recom-
mendation would require the development of immunological reagents 
and resources currently not present in the NHP field. Moreover, a variety 
of challenge models and systems are likely to be necessary to provide 
sufficient depth and breadth of understanding. Concentrating on the 
initial 1-10 days after inoculation would require altering the way most 
NHP experiments are designed and conducted.
B. PrIorItIes And recommendAtIons
Priority 1: optimizing the clinical trials Process by Accelerating 
the Pace of trials and enriching their scientific component
The pace of HIV vaccine efficacy trials is unacceptably slow (Fig. 1). 
The four to six year gap between initiation of a trial and its efficacy 
and scientific results prevents us from fully capitalizing on the valuable 
knowledge produced during these expensive and complex endeavors. 
There is a need to speed up the iterative feedback between vaccine evalu-
ation and discovery, to increase the pace and number of human clinical 
trials, to broaden their scientific purpose, and to establish mechanisms 
to integrate and evaluate novel assays of human immune responses in 
trials.
recommendations
In order to increase the scientific impact of clinical trials, extensive 
laboratory search for correlates of protection needs to be discussed and 
planned before the trial is initiated. Immunologists and virologists need 
to be actively engaged in efficacy trial design at the earliest stages to 
formulate hypotheses that can be tested in the course of the trial, ensure 
that the very best science is brought to bear on the trial, and agree on a 
sampling regimen, whose frequency, timing and nature are optimized 
for these studies.
Given the complexities of HIV vaccine design, the likely primary 
output of the next several trials will be to provide critical leads to the 
development of improved vaccine regimens. These leads need to be 
explored and communicated to the scientific community as quickly 
as possible, preferably within two years from study initiation, so that 
they can be leveraged to rapidly initiate new preclinical studies or 
further clinical evaluation of vaccine concepts. In order to accelerate 
the search for correlates, we need to explore ways to initiate the labora-
tory work much sooner, well before the trial is completed. This may 
require mechanisms to partially unblind the samples for the laboratory 
analyses without compromising the integrity of the trial or regula-
tory norms and regulations. Significant time savings from the pre-hoc 
planning and faster execution of laboratory work will translate into 
more than incremental acceleration of the vaccine discovery process. 
More efficient vaccine trials will allow a more thorough and more 
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table 1.  Areas in the nHP field requiring increased attention 
and support.
• Optimization of NHP models (new viruses, challenge procedures and 
approaches)
• Development of new reagents to manipulate NHP responses in vivo
• Systems biology approaches in the NHP model
• Training of scientists in NHP models
• Promoting increased collaboration amongst NHP scientists
• Promoting interaction between NHP and clinical scientists
• Strategies for cost-reduction of NHP experiments
• Strategies to increase statistical power of NHP experiments
Trial start/end
Trial analysis/results
First correlates
VaxGen USA Trial
VaxGen Thai Trial
Step Trial
RV144 Trial1
1995 2000 2005 2010
Figure 1  Timeline of HIV Vaccine Efficacy Trials. 1Data on potential 
correlates of protection from RV144 are expected in 2011.
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humans and NHPs in their immune responses to infection, vaccination 
and challenge, and post-vaccination infection. Optimization of existing 
NHP resources and closer integration with clinical scientists will allow 
the field to address many of the challenges currently facing the field 
(Table 1).
c. conclusIons
A multidisciplinary approach to clinical trials calls for the bring-
ing together of basic scientists, NHP model researchers and clinical 
researchers into a coherent scientifically-rich clinical trials endeavor 
(Table 2). This integration will be based upon active engagement of all 
parties, re-allocation of existing resources and attraction of new sources 
of funding. If we are to develop an effective vaccine as rapidly as pos-
sible, different vaccine concepts may need to be tested in human efficacy 
trials as quickly as possible. Resources to fund and provide access for 
GMP lots of candidate immunogens for these clinical trials need to be 
established. An increase in the number of efficacy trials is also essential 
to sustain the HIV vaccine endeavor, create the necessary momentum 
and opportunities for evidence-based improvements in vaccine design, 
and explore a critical and diverse number of vaccine concepts. This will 
require a significant increase in investment, but the observed efficacy of 
the RV144 trial candidate justifies the additional costs needed to boost 
the exploratory search for correlates of protection within efficacy trials. 
These changes critically depend on more active engagement of basic 
and NHP researchers in clinical trial design, increased access to human 
samples, and accelerated translation of new fundamental insights into 
relevant clinical settings.
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organizational processes to encourage coordination and collaboration 
among primate researchers/centres. These incentives should stimulate 
innovative, investigator-initiated studies, while at the same time enable 
scale-up capacity within a larger group environment when necessary. 
Collaborations within the NHP field will optimize the utilization of 
global NHP research capacity (infrastructure, committed scientists 
and cross-cutting, novel technologies) and provide the resources and 
organizational structure to efficiently support properly powered and 
controlled NHP studies to define mechanisms of immunity and of infec-
tion prevention/control. At the same time, interdisciplinary consortia, 
bringing together NHP researchers and clinical scientists, would greatly 
enable experiments to define the similarities and differences between 
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table 2.  summary of priorities and recommendations
Priority 1. optimizing the clinical trials Process by Accelerating the Pace 
and number of trials and enriching their scientific component
• Ensure that we maximize what is learned from every trial by incorporating 
the latest advances into clinical trial design
• Explore novel approaches to the design and analysis of clinical trials
• Develop scientific and clinical capacity in countries and regions where 
clinical trials are executed
• Develop the resources and mechanisms of access for GMP production of 
candidate immunogens for human clinical trials
• Broaden and augment the funding base in order to increase the quantity 
and complexity of efficacy trials
Priority 2. optimize the use of nHPs through improved relevance to humans 
and closer integration of preclinical and clinical research
• Focus research on questions that can be uniquely answered in NHP models 
and to study mechanisms of protection rather than to use as a gatekeeper for 
human trials
• Establish NHP consortia or groups to leverage resources, promote standard-
ization, and exchange ideas
• Establish interdisciplinary consortia of NHP researchers with clinical 
scientists to define similarities and differences between humans and NHPs 
in immune response to infection, vaccination and challenge, as well as in 
breakthrough infections.
• Expand and maximize the utilization of global NHP research capacity 
(infrastructure, committed scientists and novel technologies)
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